INGN Stock Analysis: Buy, Sell, or Hold?
INGN - Inogen Inc
$6.15
0.04 (0.66%)
▲
5d:
-2.69%
30d:
-0.48%
90d:
-8.34%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 06, 2026
Get Alerted When INGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INGN shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: INGN shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: INGN is currently trading at $6.15, which is considered fair relative to its 30-day fair value range of $5.99 to $6.40. From a valuation perspective, the stock is trading at a discount (Forward PE: -19.7) compared to its historical average (120.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, INGN is in a strong downtrend. Immediate support is located at $5.86, while resistance sits at $6.66.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.00 (+112.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INGN is in a strong downtrend. Immediate support is located at $5.86, while resistance sits at $6.66.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $13.00 (+112.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$5.99 -
$6.40
Company Quality Score
56/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
75.8%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 112.8% below Wall St target ($13.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Fair Price Analysis
30-Day Fair Range
$5.99 -
$6.40
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$0.56
(9.2%)
Support & Resistance Levels
Support Level
$5.86
Resistance Level
$6.66
Current Trend
Strong Downtrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-19.71
Wall Street Target
$13.00
(+112.8%)
Revenue Growth (YoY)
2.0%
Earnings Growth (YoY)
87.3%
Profit Margin
-6.5%
PE vs Historical
-19.7 vs 120.2
CHEAP
Share & Embed Analysis
Last updated: March 31, 2026 1:33 PM ET
Data refreshes hourly during market hours. Next update: 2:33 PM
Data refreshes hourly during market hours. Next update: 2:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 60 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 56 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 51 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 61 BUY |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
